Original Article
Heat shock protein 90 inhibition by 17-Dimethylaminoethylamino-17-demethoxygeldanamycin protects blood-brain barrier integrity in cerebral ischemic stroke

Jia Qi1*, Yan Liu1*, Ping Yang1*, Ting Chen1, Xin Zhu Liu1, You Yin2, Jian Zhang1, Feng Wang3
1Department of Pharmacy, School of Medicine, Xinhua Hospital Affiliated to Shanghai Jiaotong University, China; 2Department of Neurology, Changzheng Hospital Affiliated to Second Military Medical University, China; 3Department of Neurology, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, China.
*Equal Contributors.

Received April 9, 2015; Accepted June 24, 2015; Epub October 15, 2015; Published October 30, 2015

Abstract: Metalloproteinase (MMP)9 plays a pivotal role in ischemic stroke induced blood brain barrier (BBB) disruption. Correlation between HSP90 and MMP9 in several diseases prompted us to evaluate the efficacy of HSP90 inhibition as a novel approach to protect BBB integrity in ischemic stroke. ELISA was used to detect HSP90α and MMP9 in serum samples of stroke patients, which showed that HSP90α significantly correlated with MMP9 among 63 serum samples of stroke patients. Male C57/BL6 mice were pretreated with 17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or vehicle before being subjected to transient occlusion of middle cerebral artery and reperfusion (MCAO). Infarction, neurological scores, Evans blue (EB) extravasation, inflammatory responses and tight junction protein expression were examined 24 h after MCAO. We also investigated if 17-DMAG protected BBB integrity by suppressing inflammation and MMP9 activation. Oxygen glucose deprivation (OGD) was performed on bEnd.3 cells to explore the mechanisms of HSP90 inhibition in inhibiting MMP9. The results demonstrated that infarct volume was reduced in 17-DMAG-treated mice compared to control group following MCAO. Neurological outcomes were greatly improved in 17-DMAG-treated mice. Inflammatory responses, MMP9 activity and EB extravasation were decreased by 17-DMAG. In addition, 17-DMAG inhibited nuclear factor kappa B (NF-κB) activation following MCAO. Furthermore, HSP90 inhibition decreased NF-κB dependent MMP9 expression in bEnd.3 after OGD /reoxygenation. These findings suggested that HSP90 could be a novel therapeutic target in BBB breakdown during ischemic stroke. As several HSP90 inhibitors are in clinical trials for cancer, these findings have translational implications.

Keywords: Blood brain barrier, inflammation, ischemic stroke, heat shock protein 90

Introduction
Ischemic stroke is the second most common cause of death and the most frequent cause of disability worldwide [1]. Tissue plasminogen activator (tPA) remains the only US Food and Drug approved treatment for ischemic stroke. Due to an increased risk of hemorrhagic transformation, only 5% patients are eligible for tPA treatment [2]. Moreover, tPA may cause injury to blood-brain barrier (BBB) through activating matrix metalloproteinases (MMPs) [3]. Therefore, it is imperative to develop new combination therapies for ischemic stroke.

Disruption of BBB is a hallmark of stroke pathogenesis, which results in vasogenic edema formation and further brain damage [4]. Increased expression of MMPs has been reported to play an important role in stroke-induced BBB leakage through degrading the TJ proteins and basal proteins [5, 6]. In particular, an increase in serum MMP9 was observed and related to more severe stroke in patients [7]. MMP9 KO or pharmacological inhibition provides strong neuroprotection and attenuates proteolysis of BBB in mouse model of transient middle cerebral artery occlusion (MCAO) [8-10]. Although the exact cell sources for the MMP9 generation
HSP90 inhibition protects blood brain barrier
during focal cerebral ischemia are not yet defined in vivo, microglial activation has been evidenced to potentiate damage to components of the BBB under ischemia-like conditions [11]. Thus, inhibition of inflammation may decrease MMPs and attenuate the disruption of BBB.

The heat shock protein (HSP) 90 is an important molecular chaperone for protein folding, intracellular disposition and assembly of many proteins, including key mediators of signal transduction and transcriptional regulation. Previous study has demonstrated that HSP90α is over expressed in animal model of cerebral ischemia [12, 13]. In other diseases, the levels of HSP90 and MMP9 have been demonstrated to be correlated with each other [14, 15]. However, no studies have been conducted on HSP90α level in human stroke and the association with MMP9.

17-dimethylaminoethylamino-17-demethoxygedanamycin (17-DMAG) is a selective HSP90 inhibitor currently undergoing clinical trials against cancers, which block the ATP-binding site of HSP90 and exert pleiotropic functions, which include induction of the heat shock response and degradation of some client proteins. Moreover, many studies have found that HSP90 inhibition by 17-DMAG protects the brain against ischemic injury through inhibiting inflammation and reducing MMP9 after ischemia [16].

Therefore, the aim of our study is to demonstrate the relationship of HSP90α level with MMP9 in stroke patients, and examine the protective effect of HSP90 inhibition by 17-DMAG on BBB in mouse model of MCAO. As several HSP90 inhibitors have been demonstrated a favorable safety profile in clinical trials in cancer patients, our results may have translational implications.

Materials and methods

Study subject

Subjects were enrolled in the study from February 2012 to July 2013 and were approved by the institutional Review board of Shanghai Jiaotong University, and gave informed consent. The age and gender from the control group matched that of the stroke patients. Demographic changes, associated laboratory inspection, imaging information were also collected to analyze. Whether subjects taking medicines including antidiabets, hypotensor or platelet aggregation drugs was also recorded. The exclusion criteria included recurrent stroke, intracranial tumor, multiple trauma, hematological system diseases, renal or liver failure, acute infectious diseases and other diseases affecting the hemogram. If the time from the onset of stroke symptoms to blood sample collection was longer than 24 hours, the patient was excluded. The risk factors were defined as following: hypertension: blood pressure above 140/90 mmHg; hyperlipidemia: total cholesterol level ≥ 0.7 mmol/L, triglyceride level ≥ 1.8 mmol/L and HDL level < 1 mmol/L; Diabetes mellitus: fasting blood glucose level > 6.1 mmol/L or HbA1c ≥ 7%.

Transient middle cerebral artery occlusion model and drug administration

All animal protocols have been approved by Institutional Animal Care and Use Committee of Shanghai Jiao Tong University, Shanghai, China. tMCAO was carried out as previously described [17]. 17-DMAG (0.2 mg/kg) or vehicle was intraperitoneally injected immediately after MCAO. The optimal dose is based on previous study [18].

Measurement of physiological parameters

Regional cerebral blood flow (rCBF) was measured by the probe of laser-Doppler flowmetry (MoorLDI2; Moor Co., Ltd., U.K.) as previously described [19]. In randomly selected animals, mean arterial pressure was monitored, and arterial blood pH, pCO₂, and pO₂ were measured before MCAO operation, during (10 min after MCAO), and 30 min after reperfusion (Rapid Lab 248, Bayer, Wuppertal, Germany). Core temperature as maintained at about 37°C ± 5°C during the surgery.

Infarct volume measurement

Infarct volume was measured using TTC staining as previously described [17]. The relative infarct size measure was calculated with the following equation: relative infarct size = (contralateral area–ipsilateral non-infarct area)/contralateral area.

Neurobehavioral assessments

Neurological assessments were performed by an experimenter blind to the treatment conditions at 24 h after MCAO. The neurological findings were scored on a 4-point scale: 0 (no neu-
HSP90 inhibition protects blood brain barrier

Table 1. Primer lists

<table>
<thead>
<tr>
<th>Primer</th>
<th>Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mouse MMP-9 promoter</td>
<td>5′-GCCGACAAAGGGGTGTGTTTTG-3′ and</td>
</tr>
<tr>
<td></td>
<td>5′-TGACTGACCTCTCTCTGG-3′ for p65</td>
</tr>
<tr>
<td>Mouse MMP-9</td>
<td>5′-GATCCCCAGACGCTTACCT-3′</td>
</tr>
<tr>
<td>Mouse IL-1β</td>
<td>5′-CCTGACAGCAGAGTTGGG-3′</td>
</tr>
<tr>
<td>Mouse MCP-1</td>
<td>5′-GCTTCTGACCTCTCTGG-3′</td>
</tr>
<tr>
<td>18S rRNA</td>
<td>5′-TCAGACGCAAGCTGGAGG-3′</td>
</tr>
<tr>
<td></td>
<td>5′-GGACATCTAAGGGCATTAC-3′</td>
</tr>
</tbody>
</table>

Evans blue extravasation

Evans blue extravasation was measured as previously described [21]. Briefly, EVANS blue (2% in saline, 4 ml/kg; Sigma) was administered intraperitoneally at the onset of reperfusion. Mice were transcardially perfused with saline to remove the intravascular dye at 22 hours after reperfusion. Each hemisphere was weighed rapidly, homogenized in 1 ml of 50% trichloroacetic acid (wt/vol), and then centrifuged (12,000*g for 20 minutes). The supernatant was collected and mixed with ethanol (1:3). The concentration of Evans blue was determined by measuring the 610 nm absorbance with spectrophotometry. The results were expressed as Evans blue (μg)/tissue (g) calculated against a linear standard curve.

Gelatin zymography for MMP9

The evaluation of MMP9 activity in conditioned media form cells cultures or homogenates of brain tissue was performed by zymography as described previously [22].

Enzyme-linked immunosorbent assay (ELISA)

Blood samples were drawn from peripheral veins and were clotted for 30 min. After centrifuging at 4°C for 10 min, serum was stored at -20°C until assayed. The levels of human plasma HSP90α and MMP9 were measured by ELISA kits (Westang Bio-Tech, Shanghai, China) according to the manufacturer’s protocols.

Cell cultures

A transformed mouse brain endothelial cell line, bEnd.3 cells were purchased from the American Type Culture Collection (Manassas, VA) and cultured in medium (DMEM supplemented with 10% fetal bovine serum, 2 mM glutamine, and 1 × antibiotic/antimycotic; Invitrogen, Carlsbad, CA) at 37°C in a humidified incubator (10% CO2, 90% air).

Oxygen-glucose deprivation

To simulate ischemic conditions, cultures were subjected to oxygen glucose deprivation (OGD). Before induction of OGD, serum-containing media were removed from the cell cultures before adding low-glucose medium (1.0 g/L,
HSP90 inhibition protects blood brain barrier

supplemented DMEM). The cultures containing low-glucose medium were placed in a hypoxia chamber (Billups-Rothenburg, Del Mar, CA, USA), which was flushed through with a mixture of 95% N₂ and 5% CO₂ for 1 hour, and then closed for the duration of the experiment. O₂ levels decreased to 0.1% to 0.4% at 4 hours, and were maintained throughout the experiment (18 hours total).

Transfection of small-interfering RNA

scrambled siRNA (Ambion) or HSP90 (Santa Cruz) siRNA was transfected with HiPerFect Transfection Reagent (Qiagen, Shanghai, China). The ability of the siRNA to inhibit HSP90 expression was assessed 48 h post-transfection by western blot.

Chromatin immunoprecipitation (CHIP) assay for NF-κB and MMP9 promoters binding

ChiP assays were performed with a chip kit (Millipore, Billerica, MA) according to manufacturer’s instructions. Briefly, Chromatin was cross-linked by adding formaldehyde to cell culture medium for 10 min at room temperature. Cross-linking reaction was ceased by glycine solution. Cross-linked chromatin was sheared by supersonic at 4℃. Debris was removed by centrifugation and supernatants were collected. The purified chromatin was immunoprecipitated with p65 antibody from Santa Cruz Biotechnology and normal rabbit IgG from Millipore. The DNA/Protein complexes were collected by the use of Protein G-agarose beads. Beads were washed and bound DNA was eluted. After reverse cross-linking reaction and pro-

Table 2. Patients characteristics

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>Acute ischemic stroke</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>LA</td>
<td>CE</td>
<td>SA</td>
</tr>
<tr>
<td>N</td>
<td>50</td>
<td>20</td>
<td>23</td>
</tr>
<tr>
<td>Age (years, mean ± SD)</td>
<td>64.1 ± 6.91</td>
<td>68.1 ± 8.23</td>
<td>62.1 ± 9.56</td>
</tr>
<tr>
<td>Race (Asia, %)</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
</tr>
<tr>
<td>Ethnicity (Han, %)</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
</tr>
<tr>
<td>Hypertension (N, %)</td>
<td>5 (33.3%)</td>
<td>16 (80%)</td>
<td>15 (65%)</td>
</tr>
<tr>
<td>Diabetes (N, %)</td>
<td>2 (13.3%)</td>
<td>14 (70%)</td>
<td>8 (35%)</td>
</tr>
<tr>
<td>Hyperlipidemia (N, %)</td>
<td>3 (20%)</td>
<td>12 (60%)</td>
<td>10 (43%)</td>
</tr>
<tr>
<td>Cardiopathy (N, %)</td>
<td>5 (10%)</td>
<td>0 (0%)</td>
<td>23 (100%)</td>
</tr>
<tr>
<td>NHISS (Mean, Min, Max)</td>
<td>NA</td>
<td>4.89 (1, 11)</td>
<td>5.01 (0, 19)</td>
</tr>
</tbody>
</table>

Figure 1. Blood level of HSP90α and the correlation analysis between HSP90α and MMP9 in acute ischemic stroke.

A. HSP90α was highly expressed in acute stroke patients. *p < 0.05, vs. control. n = 50 in control group, n = 64 in total patients. B. The scatterplot showed MMP9 levels were positively associated with HSP90α level. R = 0.352, p < 0.01.
HSP90 inhibition protects blood brain barrier

Table 3. Physiological parameters

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Group</th>
<th>Before</th>
<th>During</th>
<th>After</th>
</tr>
</thead>
<tbody>
<tr>
<td>rCBF (%)</td>
<td>vehicle</td>
<td>100</td>
<td>12.7 ± 3.3</td>
<td>95.7 ± 8.6</td>
</tr>
<tr>
<td></td>
<td>DM</td>
<td>100</td>
<td>10.4 ± 3.9</td>
<td>93.2 ± 9.4</td>
</tr>
<tr>
<td>MABP (mmHg)</td>
<td>vehicle</td>
<td>94.3 ± 4.9</td>
<td>92.5 ± 9.8</td>
<td>88.7 ± 11.2</td>
</tr>
<tr>
<td></td>
<td>DM</td>
<td>98.4 ± 7.6</td>
<td>94.3 ± 7.9</td>
<td>91.3 ± 8.1</td>
</tr>
<tr>
<td>PCO₂ (mmHg)</td>
<td>vehicle</td>
<td>46.9 ± 6.4</td>
<td>46.4 ± 4.9</td>
<td>47.9 ± 6.3</td>
</tr>
<tr>
<td></td>
<td>DM</td>
<td>49.8 ± 7.3</td>
<td>49.9 ± 7.1</td>
<td>46.8 ± 5.9</td>
</tr>
<tr>
<td>PO₂ (mmHg)</td>
<td>vehicle</td>
<td>130.5 ± 19.9</td>
<td>119.5 ± 16.4</td>
<td>135.4 ± 25.9</td>
</tr>
<tr>
<td></td>
<td>DM</td>
<td>129.6 ± 21.8</td>
<td>124.8 ± 19.5</td>
<td>131.9 ± 19.5</td>
</tr>
<tr>
<td>Temperature (°C)</td>
<td>vehicle</td>
<td>36.8 ± 0.3</td>
<td>36.9 ± 0.2</td>
<td>37.0 ± 0.4</td>
</tr>
<tr>
<td></td>
<td>DM</td>
<td>37.2 ± 0.2</td>
<td>36.8 ± 0.1</td>
<td>37.2 ± 0.3</td>
</tr>
</tbody>
</table>

Results

Patients and clinical data

The study was approved by the Institutional Review Board and Human Ethics Committee of Shanghai Jiaotong University. Written consent for using the samples for research purposes was obtained from all patients prior to research. The clinical characteristics of ischemic stroke patients and healthy control are listed in Table 2. On admission, the ages of patients were 66.7 ± 9.28 and the ages of healthy control were 64.1 ± 6.91 (p > 0.05). There is no significant differences in gender between control and patients. To eliminate unmatched factor impact on HSP90α expression levels between healthy subjects and stroke patients, a logistic regression was performed, which suggested the HSP90α levels was a stroke risk factor.

The levels of blood HSP90α in acute ischemic stroke patients

ELISA for HSP90α showed that HSP90α level in serum from 64 patients is higher than serum from 50 healthy subjects (Figure 1A). No difference was observed between subtypes. In addition, we also analyzed the difference between patients with / without antidiabetes, hypotension or platelet aggregation. No significant difference of the expression levels of HSP90α was found.

The correlation between HSP90α and MMP9 level of stroke patients’ serum

HSP90α protein expression was reported to be significantly associated with MMP9 expression in human gastric carcinoma tissues and chronic kidney disease [14, 15]. Therefore, we investigated the relationship of HSP90α and MMP9 protein level in stroke. The level of serum MMP9 was positively associated with HSP90α level (Figure 1B, r=0.352, p<0.01).
Effects of 17-DMAG on physiological parameters

The effects of 17-DMAG on regional cerebral blood flow, arterial blood pressure, pH, pO\textsubscript{2}, and pCO\textsubscript{2} were evaluated in mice after MCAO. No significant difference was observed between 17-DMAG- and vehicle-treated groups in any of the respiratory and cardiovascular parameters tested (Table 3).

The effect of 17-DMAG on HSP90 and HSP70 expression

The heat shock response is a powerful cellular defense mechanism against a variety of insults. As shown in Figure 2, HSP90α and HSP70 expression was significantly increased in the mouse ischemic cortex. 17-DMAG and its analogues have been shown to disassociate the interaction of HSP90 with HSF1, which subsequently induces the expression of HSP70. Therefore, assessment of HSP70 induction has been used as a useful pharmacodynamic marker of HSP90 inhibition. Indeed, 17-DMAG treatment markedly increased HSP70 expression in ischemic cortex, but without effect on HSP90.

17-DMAG reduced infarction, improved neurological deficits and inhibited BBB disruption

MCAO was performed to determine the effect of HSP90 inhibition on cerebral ischemia. As shown in Figure 3A, cortical blood flow was successfully decreased by 80% after occlusion. HSP90 inhibition by 17-DMAG both reduced infarct volume (Figure 3B) and protected BBB integrity (Figure 3C). 17-DMAG also improved...
HSP90 inhibition protects blood brain barrier

Figure 4. 17-DMAG attenuated MCAO-induced MMP9 elevation and tight junction degradation. A. Zymography showed that 17-DMAG inhibited the elevation of total MMP9 activities 24 hr after reperfusion. B. qPCR showed that 17-DMAG inhibited the increase of MMP9 mRNA expression. C, D. 17-DMAG restored Occludin and ZO-1 downregulation. *p < 0.05, compared with sham group, #p < 0.05, compared with MCAO group n = 8/group.

Figure 5. 17-DMAG inhibited inflammatory responses in the ischemic cortex. A. Representative IBA1 staining within the ischemic cortex of mice following MCAO show less intense staining in 17-DMAG treated mice. B. Fewer IBA1 (n = 8/group) were detectable in the peri-infarct regions of 17-DMAG treated mice, compared with vehicle treated mice (n = 7/group). C, D. qPCR showed that 17-DMAG inhibited the increase of IL-1β and MCP-1 mRNA expression. (**p < 0.01, compared with sham group; ###p < 0.01, compared with MCAO group).
neurological deficits of MCAO mice at 24 h after reperfusion compared to vehicle (Figure 3D).

**17-DMAG attenuated MCAO-induced MMP9 elevation and tight junction degradation**

MMP9 activities in cortex of MCAO mice were investigated by zymography. Consistent with previous studies, MMP9 activity was strongly increased in MCAO mice, whereas 17-DMAG treatment significantly suppressed the induction of MMP9 activity in cortex (Figure 4A). Real-time PCR showed that 17-DMAG treatment significantly suppressed MMP9 gene expression induced by MCAO, similar to the results obtained with zymography (Figure 4B). Conversely, protein levels of Occludin and ZO-1, tight junction proteins involved in BBB integrity, were markedly decreased in MCAO group, which were robustly prevented by 17-DMAG treatment (Figure 4C and 4D).

**17-DMAG suppressed inflammatory responses in the ischemic brain**

Local inflammation responses contribute to BBB disruption induced by MCAO [23]. Microglia are stimulated within hours after ischemia onset, followed by upregulation of a variety of inflammatory factors [24]. We quantified the number of activated microglia (assessed by IBa1 staining) in the peri-infarct region within the ipsilateral ischemic cortex. Regions of interest were selected based on criteria published previously [25]. Figure 5A shows more intensely stained IBa1-positive cells in a brain section of a vehicle treated mice compared with 17-DMAG treated mice at 24 h after MCAO. Gene expression profiles of pro-inflammatory cytokines in the ischemic cortex were also examined. As expected, compared to sham group, MCAO significantly induced mRNA expression of IL-1β and MCP-1, which was remarkably attenuated by 17-DMAG (Figure 5C and 5D).

**17-DMAG suppressed NF-κB activation in ischemic brain**

NF-κB activation has been reported to up-regulate transcription of various inflammatory genes including MMP9 after cerebral ischemia [26]. Nuclear translocation of NF-κB p65 subunit is an indicator of NF-κB activation.
HSP90 inhibition protects blood brain barrier

Compared to sham group, elevated p65 in the nuclear fraction and reduced p65 levels in cytoplasmic fraction were observed in ischemic cortex at 24 h after MCAO. 17-DMAG treatment inhibited MCAO-induced nuclear translocation of p65 in ischemic cortex (Figure 6A). Activation of NF-κB requires phosphorylation of IkBα by IKK and degradation by the proteasome, allowing NF-κB to transfer to the nucleus. Therefore, we also investigated the effects of HSP90 inhibitors on IKK expression. As expected, 17-DMAG inhibited IKK expression in vivo (Figure 6B).

**HSP90 inhibition suppressed MMP9 secretion and gene expression in bEnd.3 cells via inhibition of NF-κB pathway**

As NF-κB transcription factor is essentially involved in regulating MMP9 expression in bEnd.3 cells [27], we investigated whether 17-DMAG/17-AAG inhibits expression of MMP9 via inhibition of NF-κB transcriptional activity. 17-DMAG dose dependently inhibited MMP9 mRNA expression (Figure 7A). However, treatment of mouse bEnd.3 cells with OGD markedly increased the activity and mRNA levels MMP9, which were significantly inhibited by treatment of cells with 17-DMAG/17-AAG (Figure 7B and 7C).

Because the promoter region of MMP9 has a proximal NF-κB binding site that is functionally critical for the augmented production of MMP9, we then investigated the effect of 17-DMAG/17AAG on NF-κB binding to the MMP9 promoters in bEnd.3 cells by ChIP assays. In microglial cells, OGD treatment markedly increased the binding of NF-κB to MMP9 promoters, as shown in OGD-treated cells, after immunoprecipitation with primary antibody to p65, but not with control immunoglobulin G (IgG). Importantly, 17-DMAG/17AAG markedly attenuated the NF-κB binding to MMP9 promoters (Figure 7D). Taken together, these results indicate that HSP90 inhibitors inhibit OGD-induced expression of MMP9, at least in part, via inhibition of NF-κB transcriptional activity (Figure 7E).
To study the specific effect of HSP90 inhibition, we measured basal MMP9 production under genetic silencing of HSP90. We found that genetic inhibition of HSP90 decreased MMP9 mRNA expression (Figure 7F).

Discussion

It is well established that the heat shock protein 90 (HSP90) is over expressed and significantly correlated with MMP9 in many malignancies [14]. Studies on brain tissue and serum of patients suffering ischemic stroke demonstrated that MMP9 may play an important role in BBB disruption during ischemic stroke under clinical condition [28-30]. Previous study has demonstrated that HSP90 is over expressed in animal model of cerebral ischemia [12]. In this study, we observed HSP90 expressed higher and correlated with MMP9 significantly in serum of ischemic stroke patients (Figure 1A and 1B), which suggested that HSP90 may be a key molecule for increased MMP9 expression and subsequent BBB disruption in ischemic stroke.

Although the inhibitors of HSP90 are of therapeutic interest primarily in cancer [31], evidence is emerging for the potential beneficial role of HSP90 inhibitors in the treatment of other inflammatory diseases including ischemic stroke [19]. Indeed, one major mechanism underlying ischemic stroke-induced BBB disruption is enhanced inflammatory responses [23]. Particularly, pro-inflammatory cytokine induction of MMP9 expression and activity is a major cascade in destructive opening of BBB after stroke [32]. Importantly, inhibition of MMPs by the broad-spectrum MMP inhibitor minocyline has been shown to inhibit BBB disruption in ischemic stroke [33]. In agreement with previous studies, our data demonstrated that HSP90 inhibitor 17-DMAG significantly decreased infarct volume and inflammatory responses in MCAO mice (Figures 3 and 5). Consistent with these observations, 17-DMAG reduced the expression and activity MMP9 both in vivo and in bEND cells (Figures 4 and 7). It is well known that tight junction proteins such as occludin and ZO-1 are essential components of BBB and known to be substrates of MMPs [22]. Our data show that occludin and ZO-1 were rapidly degraded following MCAO and 17-DMAG significantly inhibited degradation of these proteins (Figure 4C and 4D). Taken together, these results suggest that 17-DMAG effectively prevents BBB disruption, in part by inhibiting degradation of tight junction proteins via inhibition of inflammatory responses and subsequent MMP9 expression after ischemic stroke.

Among the different client proteins of HSP90 involved in inflammatory diseases, NF-κB is one of the most representative examples. NF-κB activation has been reported to up-regulate transcription of various inflammatory genes including MMP9 after cerebral ischemia [26]. Indeed, both genetic and pharmacological inhibition of NF-κB pathway has been reported to protect against ischemic stroke [34]. Since IKK exists in complexes with HSP90, disruption of these complexes by HSP90 inhibitors may block IKK function and subsequent NF-κB activation. In accordance with this hypothesis, we found that inhibition of HSP90 by 17-DMAG markedly attenuated the IKK expression and MMP9 secretion in MCAO mice. Likewise, we further demonstrated that 17-DMAG potently inhibited the binding of P65 to the promoter regions of MMP9 in bEnd.3 cells.

The protective effects of HSP90 inhibitors in inflammatory diseases could be due to up-regulation of antiinflammatory HSP expression (especially HSP70) [35]. Moreover, mice over-expressing HSP70 showed decreased number of activated macrophages and inhibition of NF-κB in ischemic stroke [36]. Therefore, further studies are needed to clarify whether the anti-inflammatory effects observed with HSP90 inhibitors is due to HSP70 up-regulation, inhibition of HSP90 client proteins, or both.

In conclusion, HSP90α was overexpressed and correlated with MMP9 level in patients with ischemic stroke. Inhibition of HSP90 by 17-DMAG markedly attenuated BBB disruption following cerebral ischemia in mice through inhibiting degradation of tight junction proteins via inhibition of inflammatory responses and subsequent MMP9 expression. Currently, more than 10 HSP90 inhibitors in various oncological indications are undergoing clinical trials [37]. Therefore, our findings may have direct translational implications for ischemic stroke, especially hemorrhagic transformation after stroke.

Acknowledgements

This study was supported by funds from Shanghai Municipal Commission of Health and
HSP90 inhibition protects blood brain barrier

Family Planning (201540301), and Natural Science Foundation of Shanghai (15ZR1414-600).

Disclosure of conflict of interest

None.

Address correspondence to: Dr. Feng Wang, Department of Neurology, Shanghai General Hospital, Shanghai Jiaotong University, China. E-mail: wfwangfeng@yahoo.com; You Yin, Department of Neurology, Shanghai Changzheng Hospital Affiliated to Second Military Medical University, China. E-mail: Yinyou179@163.com; Jian Zhang, Department of Pharmacy, School of Medicine, Xinhua Hospital Affiliated to Shanghai Jiaotong University, China. E-mail: zjboss@126.com

References


[19] Qi J, Han X, Liu HT, Chen T, Zhang JL, Yang P, Bo SH, Lu XT and Zhang J. 17-Dimethy-
HSP90 inhibition protects blood brain barrier


